BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25684486)

  • 1. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
    Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
    Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
    Ho HL; Kao HL; Yeh YC; Chou TY
    Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogenic immunohistochemical quadruplex provides accurate diagnostic differentiation of non-small cell lung cancer.
    Roberts EA; Morrison LE; Behman LJ; Draganova-Tacheva R; O'Neill R; Solomides CC
    Ann Diagn Pathol; 2020 Apr; 45():151454. PubMed ID: 31923744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma".
    Shigeta N; Yokose T; Murakami S; Isaka T; Shinada K; Yoshioka E; Narita A; Katakura K; Kondo T; Kato T; Nagashima T; Saito H; Ito H
    Thorac Cancer; 2024 Feb; 15(6):458-465. PubMed ID: 38197164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma.
    Miyamae Y; Shimizu K; Hirato J; Araki T; Tanaka K; Ogawa H; Kakegawa S; Sugano M; Nakano T; Mitani Y; Kaira K; Takeyoshi I
    Oncol Rep; 2011 Apr; 25(4):921-8. PubMed ID: 21318227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.
    Thunnissen E; Borczuk AC; Flieder DB; Witte B; Beasley MB; Chung JH; Dacic S; Lantuejoul S; Russell PA; den Bakker M; Botling J; Brambilla E; de Cuba E; Geisinger KR; Hiroshima K; Marchevsky AM; Minami Y; Moreira A; Nicholson AG; Yoshida A; Tsao MS; Warth A; Duhig E; Chen G; Matsuno Y; Travis WD; Butnor K; Cooper W; Mino-Kenudson M; Motoi N; Poleri C; Pelosi G; Kerr K; Aisner SC; Ishikawa Y; Buettner RH; Keino N; Yatabe Y; Noguchi M
    J Thorac Oncol; 2017 Feb; 12(2):334-346. PubMed ID: 27998793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
    Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
    Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
    Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
    Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
    Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
    Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
    J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hsp90AB1 Protein is Overexpressed in Non-small Cell Lung Cancer Tissues 
and Associated with Poor Prognosis in Lung Adenocarcinoma Patients].
    Wang M; Feng L; Li P; Han N; Gao Y; Xiao T
    Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):64-9. PubMed ID: 26903158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnosis of lung biopsy employing the 2015 WHO criteria and detection of related oncogenic driver mutations].
    Fang F; Qiao XB; Yang L; Di J; Hu ST; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):270-275. PubMed ID: 30955261
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
    Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
    J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.